Bubs Australia secures permanent FDA nod for infant formula sales in US, shares jump

Bubs Australia secured permanent FDA authorization to sell three infant-formula products in the U.S. The regulatory clearance materially expands the company’s access to the U.S. infant nutrition market and put the stock on track for its largest one-day gain since May 2022.